Veradermics, Inc. (MANE) saw its stock price soar 5.55% during intraday trading on Tuesday, reflecting strong investor interest in the pharmaceutical company.
The surge follows an analyst upgrade from Citigroup, which raised its price target for Veradermics to $120 from $85. This significant increase in target price suggests growing confidence in the company's growth prospects and future valuation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.